Clinical Trials Browser

Phase 2 × INDUSTRY × EC145 × Clear all

NCT01002924 2021-04-08

Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)

Phase 2 Completed

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT01577654 2021-04-01

TARGET

Phase 2 Completed

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT00511485 2015-02-27

Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)

Phase 2 Completed

Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00507741 2015-01-07

Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)

Phase 2 Completed

Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT00722592 2015-01-07

PRECEDENT

Phase 2 Completed

Neoplasms, Ovarian Neoplasms

NCT01953536 2014-12-19

Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)

Phase 2 Withdrawn

Breast Neoplasms